FDA May Wield Prosecutorial Authority More Frequently
This article was originally published in The Gray Sheet
Executive Summary
Device companies can expect more active legal prosecution by FDA for off-label and product safety issues as the agency improves its ability to track products on the market and as the activity of industry whistleblowers grows, according to government and agency staffers
You may also be interested in...
DoJ Targets Device Labeling Accuracy In $300 Million Quest Settlement
A $302 million settlement between Quest Diagnostics and the Department of Justice announced April 15 suggests DoJ will go after device firms for knowingly misrepresenting product information in labeling and marketing materials, even if FDA is not actively investigating the matter
DoJ Targets Device Labeling Accuracy In $300 Million Quest Settlement
A $302 million settlement between Quest Diagnostics and the Department of Justice announced April 15 suggests DoJ will go after device firms for knowingly misrepresenting product information in labeling and marketing materials, even if FDA is not actively investigating the matter
Extra Caution Needed In Uncertain Period For Off-Label Info Distribution
Until FDA finalizes guidance on what practices are acceptable in distributing journal articles that describe off-label product indications, companies should watch their step in avoiding investigations that could lead to fines, criminal prosecution or exclusion from federal reimbursement programs, attorneys say